Atlas Trials

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Clinical trial NCT05802862 · COMPLETED

Trial details

NCT number
NCT05802862
Sponsor
Sunshine Lake Pharma Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes
Start date
2023-07-06
Primary completion
2024-08-16
Enrollment
414

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.